4.7 Article

Novel potential oncogenic and druggable mutations of FGFRs recur in the kinase domain across cancer types

Publisher

ELSEVIER
DOI: 10.1016/j.bbadis.2021.166313

Keywords

FGFR; Protein kinase; Somatic mutation; Protein domain; Recurrence

Funding

  1. AIRC [IG 2021-ID, 25726]
  2. Fondazione Umberto Veronesi Fellowship

Ask authors/readers for more resources

Fibroblast growth factor receptors (FGFRs) are frequently altered by single nucleotide variants (SNVs) in many human cancers, with mutations occurring at different frequencies depending on the cancer type. Mutations in the kinase domain of FGFRs, especially those occurring in tumors such as urothelial carcinoma, are potential targets for cancer therapy. The study used bioinformatics analysis to identify novel mutations in the kinase domain of FGFRs, highlighting the importance of understanding the functional impact of alterations clustering on similar residues in analogous proteins.
Fibroblast growth factor receptors (FGFRs) are recurrently altered by single nucleotide variants (SNVs) in many human cancers. The prevalence of SNVs in FGFRs depends on the cancer type. In some tumors, such as the urothelial carcinoma, mutations of FGFRs occur at very high frequency (up to 60%). Many characterized mutations occur in the extracellular or transmembrane domains, while fewer known mutations are found in the kinase domain. In this study, we performed a bioinformatics analysis to identify novel putative cancer driver or therapeutically actionable mutations of the kinase domain of FGFRs. To pinpoint those mutations that may be clinically relevant, we exploited the recurrence of alterations on analogous amino acid residues within the kinase domain (PK_Tyr_Ser-Thr) of different kinases as a predictor of functional impact. By exploiting MutationAligner and LowMACA bioinformatics resources, we highlighted novel uncharacterized mutations of FGFRs which recur in other protein kinases. By revealing unanticipated correspondence with known variants, we were able to infer their functional effects, as alterations clustering on similar residues in analogous proteins have a high probability to elicit similar effects. As FGFRs represent an important class of oncogenes and drug targets, our study opens the way for further studies to validate their driver and/or actionable nature and, in the long term, for a more efficacious application of precision oncology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available